Tempus AI is expanding its partnership with Verastem Oncology to develop a companion diagnostic (CDx) for the latter’s ...

Verastem (VSTM) announced positive updated safety and efficacy results from the RAMP 205 Phase 1/2 trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in ...

Verastem Oncology has unveiled updated early-stage data from its RAMP 205 trial in metastatic pancreatic cancer, bolstering ...

Tempus completed confirmatory testing in Verastem’s Phase 2 RAMP-201 clinical trial, which evaluated the combination of avutometinib and defactinib to treat recurrent low-grade serous ovarian ...

The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a rare type of ovarian ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

The partnership builds on the success of Verastem’s Phase 2 RAMP-201 clinical trial, which led to the U.S. Food and Drug Administration’s accelerated approval of a combination therapy for KRAS ...

Calling it a “historic first,” FDA chief Marty Makary ordered every review decision at the agency to start using a new ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Verastem Oncology’s oral combination therapy ...

The Avmapki Fakzynja Co-Pack marks the first FDA-approved treatment for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy.

In April 2025, Verastem strengthened its balance sheet by raising gross proceeds of approximately $75 million in a private placement of 3.4 million shares of its common stock and 7.3 million pre ...